Navigation Links
Fight against Fungus - A new ray of hope

Fungal infections, for many of us, though very annoying, are just a harmless fact of life. But this harmless fact turns fatal for many sick people who have weakened immune systems and cannot put up a strong defense against// attacks launched against their blood vessels and internal organs.

Doctors maintain that fungal infections though not harmful killers, can create complications in many modern medical therapies rendering them ineffective for treatment of several serious diseases. Various naturally occurring fungi in our body, occasionally cause infections in places like toenails, the mouth & the vagina. Fungi can however travel into the body in patients with weakened immune systems and cause a disease called candidiasis.

Patients who are most vulnerable to candidiasis are those who are HIV-positive, those who have received organ transplants or chemotherapy and those who have catheters inserted. Doctors say that the disease can kill 30 to 40 per cent of those infected.

Until now, the "hidden plague" of fungal infections in hospitals has been combated by two main drugs - Amphotericin B and fluconazole. While the former drug, which has been around for nearly 45years works well but with serious side effects, the latter is safer, but does not work against all strains of bacteria. A new study has however discovered a new drug that works as well as the earlier ones but without the burden of bad side effects.

Dr. John Perfect, an associate professor of medicine at Duke University and his colleagues carried out a study to test the effectiveness of the new drug called caspofungin, which is manufactured by the pharma major Merck. The study, which was funded by Merck involved testing both the new drug and old ones in nearly 250 patients from around the world.

The study concluded that the new drug, caspofungin was as effective as Amphotericin B without as many side effects. However one of the main disadvantages of the dru g, besides being new and therefore costly, is that it needs to be injected intravenously. This aspect makes it difficult to use the drug outside a hospital set-up.

The drug, which has not yet been approved for use in candidiasis patients, due to its high cost will be reserved for the sickest kinds of patients who are in the hospital and for one reason or another have not responded to fluconazole.


'"/>




Related medicine news :

1. Fight Heart disease and Pain with Meditation
2. Fight anemia by fortifying crops with iron!!!!!!!!
3. Fight arthritic pain with acupuncture
4. Smallpox Vaccine May Help Fight Cervical Cancer
5. Fight against E.coli
6. Red Wine Helps Fight Heart disease
7. Fish Oil Fights Arrhythmias, Sudden Death
8. SARS-Free Taiwan to Mark End Phase of Global Fight
9. Few Parents Help Kids Fight Acne
10. Common Cold Found to Fight Cancer
11. The Possibility Of Fighting HIV with Another Virus Questioned
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... York, NY (PRWEB) , ... April 29, 2016 , ... New York City based oral ... . This surgery is a very effective way to treat obstructive sleep apnea. Dr. Jamali ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This surgery ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... print media enterprise focused entirely on patients with cancer, today announced that Lynne ... chosen as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in the ... of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)...  Marking its one year anniversary since launching ... risk test, Color Genomics announced a ... impact the most common hereditary cancers affecting both ... analyzes hereditary cancer risks for breast, colorectal, melanoma, ... Color Test is physician ordered and includes genetic ...
(Date:4/28/2016)... 28, 2016 Dr. Vivek Ahuja ... and Ste phen Schmidt ... leading provider of cloud-based software solutions for life sciences, today announced ... bring a wealth of insight to a growing business.  This will ... George Phillips joined ArisGlobal in the position of ...
Breaking Medicine Technology: